American Academy of Neurology

American Academy of Neurology
American Academy of Neurology
American Academy of Neurology
AbbreviationAAN
Formation1948; 77 years ago (1948)
TypeLearned society and professional association
HeadquartersMinneapolis, Minnesota, U.S.
Location
Official language
English
President
Carlayne E. Jackson, MD, FAAN
President Elect
Natalia S. Rost, MD, MPH, FAHA, FAAN
CEO
Mary E. Post, MBA, CEA
Websitewww.aan.com

The American Academy of Neurology (AAN) is a professional society representing over 40,000 neurologists and neuroscientists.[1] As a medical specialty society it was established in 1948 by A.B. Baker of the University of Minnesota to advance the art and science of neurology, and thereby promote the best possible care for patients with neurological disorders. It is headquartered in Minneapolis and maintains a health policy office in Washington, D.C.

In April 2012, the academy relocated its headquarters to a new 63,000-square-foot building in downtown Minneapolis.[2] The five-story facility cost $20 million to build.[2]

Activities

Annual meeting

The annual meeting of the AAN is attended by more than 15,000 neurologists and neuroscientists from the US and abroad. The American Academy of Neurology has formal policies for avoiding conflicts of interest with pharmaceutical and device industries, and meets or exceeds all recommendations of the Council of Medical Specialty Societies Code.[3]

Top five Choosing Wisely recommendations

The AAN partnered with the American Board of Internal Medicine Foundation and Consumer Reports to provide their top 5 recommendations for neurologists. Out of 178 nominations from AAN members, these 5 guidelines were selected by a panel of 4 AAN Staff and 10 experienced AAN members who voted according to a modified Delphi method.[4] The guidelines were published in Neurology on February 20, 2013.

  1. Don't perform EEGs for headaches.
  2. Don't perform imaging of the carotid arteries for simple syncope without other neurologic symptoms.
  3. Don't use opioid or butalbital treatment for migraine except as a last resort.
  4. Don't prescribe interferon-beta or glatiramer acetate to patients with disability from progressive, non-relapsing forms of multiple sclerosis.
  5. Disrecommend for asymptomatic carotid stenosis unless the complication rate is low (<3%).

See also

References

  1. ^ "American Academy of Neurology". Neurology Today. Retrieved 25 March 2019.
  2. ^ a b Don Jacobson (June 28, 2012). "Academy of Neurology strikes right balance in its new home". The Star Tribune. Archived from the original on 2012-07-18. Retrieved 3 July 2012.
  3. ^ Hutchins, J. C.; Rydell, C. M.; Griggs, R. C.; Sagsveen, M.; Bernat, J. L.; American Academy of Neurology Pharmaceutical Device Industry Conflict of Interest Task Force (2012). "American Academy of Neurology policy on pharmaceutical and device industry support". Neurology. 78 (10): 750–754. doi:10.1212/WNL.0b013e318248e4ff. PMID 22391605.
  4. ^ Mattson, D. H.; Lisak, R. P.; Jones, D. E.; Corboy, J. R.; Larson, R.; Gronseth, G.; Getchius, T. S. D.; Langer-Gould, A.; Langer-Gould, A. M.; Gronseth, G. S.; Larson, R.; Getchius, T. S. D. (2013). "The American Academy of Neurology's Top Five Choosing Wisely recommendations". Neurology. 81 (11): 1022–1023. doi:10.1212/WNL.0b013e3182a69c98. PMID 24019388.